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Skin melanoma is a malignant tumour with aggressive behaviour. Regional or 
systemic metastases represent a form of spreading, however, the time of appearance 
should not be strictly defined. We present a case of the patient with skin melanoma, also 
suffering from multiple sclerosis, under a long-lasting high dose corticosteroid therapy. 
The primary tumour was 1.7mm thick (T2a), but the clinical course was highly 
aggressive with massive subcutaneous and lymphatic metastases involving even the 
popliteal nodes. Several surgeries were performed as the only therapeutic choice, in 
circumstances in which interferon could not be applied because of multiple sclerosis. The 
patient died 16 months after establishing the diagnosis, in the stage of generalized 
disease. It should be debated that aggressive clinical course could  be associated with 
immunosupression, however, we still cannot draw definite conclusions. Acta Medica 
Medianae 2012;51(4):47-50. 
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Introduction 
 
Malignant skin tumours have a high incidence 
among all malignant tumours worldwide. Majority 
of those tumours have origin in epithelial cells of 
the skin (basal cell carcinoma, squamous cell 
carcinoma). Although cutaneous melanoma is not 
malignancy with the highest incidence rate with 
around 5% of all malignant neoplasms worldwide 
(1), it represents a tumour with high malignant 
potency. Because of its aggressiveness, it is often 
diagnosed in advanced stages. Surgical treatment 
and reconstruction planning make it also a 
medical issue of a high clinical significance. In 
certain cirmustances, even when treated according 
to the protocol, it can be furious and hazardous. 
We present a case of the patient with skin 
melanoma, who also suffered from multiple 
sclerosis, discussing up-to-date oncologic rules 
and the influence of immunosupresion on the 
initial course. 
 
Case report 
 
A female patient, 45 years old, was admitted 
to the Clinic of Plastic and Reconstructive Surgery, 
Clinical Centre Niš, for a radical excision of a 
pigmented skin tumour, highly suspicious for 
melanoma. The patient was diagnosed with multiple 
sclerosis 10 years earlier, and was on corticosteroid 
therapy. The pigmented tumour, suspected of 
melanoma, was located on the upper left thigh. The 
surgery was performed under local anaesthesia and 
mild sedation. Tumour was radically excised with 
margins of 2cm, and the wound was directly 
closed. The wound healed without any complications. 
In the pathology report, the tumour was defined 
as cutaneous melanoma, Clark III, Breslow 
thickness 1.7mm, without ulceration, (clinical Stage 
Ib: T2a N0 M0) according to the AJCC system (2).   
Six months after the first surgery, the 
patient was admitted to the Clinic, having the 
regional spread to the left inguinal lymph nodes. 
CT scan did not reveal spreading into the 
parailiac nodes. Inguinofemoral dissection was 
performed under general anaesthesia. Three 
months after dissection, the patient was admitted 
again. There were major local metastases on the 
upper left thigh (Figure 1), and enlarged popliteal 
lymph nodes. Cosmetic operation was planned 
and performed under general anaesthesia. Local 
metastases were excised, and popliteal node 
dissection was performed. Skin defect was 
reconstructed using split thickness graft from the 
opposite thigh (Figure 2). The wound healed by 
secondary intention where margins of defect 
healed by delayed epithelisation. After three 
months we found progressive deterioration of 
health condition with the local metastases (Figure 
3). On the abdominal CT, we detected massive 
iliac and aortal lymphatic spread. Surgery was 
not performed. Patient died 16 month after Cutaneous melanoma in a patient with multiple sclerosis...                                                                             Asen Veličkov et al. 
melanoma excision, having lung and liver 
metastases.  
 
 
 
Figure 1. Metastatic disease in the skin of the left thigh 
 
 
 
Figure 2. Early postoperative view, almost the entire 
thigh was degloved and the defect was covered with 
split-thickness skin graft. In the same procedure, the 
dissection of popliteal nodes was done. 
 
 
 
Figure 3. Three months after surgery, the wound 
healed well, but new local metastases were evident on 
the surrounding skin. At this moment, the disease has 
already disseminated 
 
Discussion and review of literature 
 
Melanoma is malignancy of pigment-producing 
cells (melanocytes) located predominantly in the 
skin but also found in the eyes, ears, gastro-
intestinal tract, leptomeninges, and oral and 
genital mucous membranes. Skin melanoma was 
firstly described in 1812 by Rene Laennac (3). It 
is known for its highly malignant potency. Local, 
regional and distant metastases are not rare. In 
the USA, melanoma incidence has increased by 
3.1% annually throughout the last 20 years, 
reaching in 2007 the level of 27.5/ 100.000 in 
Caucasians, and 11.1/100000 in African-American 
population. Its incidence grows faster than the 
incidence of any other cancer (4). There are a lot 
of risk factors for melanoma, which are widely 
described in the literature. Two among them 
differentiate - genetic abnormalities and ultraviolet 
radiation (UVR) exposure (5,6).   
Although melanoma has been known for 
centuries, its therapy has not changed for a long 
time. According to the oncologic rule, the key 
therapy includes early diagnosis, and radical 
excision of the melanoma during the early stage, 
in which case there is a 90% to 99% chance of 
curing the disease (7,8). Very often, prompt 
diagnosis is not possible, and therefore we 
cannot predict whether the surgical excision will 
provide good medical outcome. 
Metastatic melanoma is by far the most 
aggressive form of skin cancer with median 
overall survival (OS) of 8 to 18 months (9). 
Prognosis for unresectable metastases or for 
advanced-stage melanoma is poor, due to its 
resistance to chemotherapy and irradiation, 
aggressive behaviour, and rapid metastasizing 
propensity. A 5-year survival rate is 78%, 59%, 
and 40% for patients with stage IIIA, IIIB and 
IIIC, respectively. One-year survival rate decreases 
from 62% to 53% and 33% for Stages M1a, M1b 
and M1c, respectively (7).  
Until 2012, there were only a few approved 
and recommended therapy modalities for advanced-
stage melanoma recommended by US Food and 
Drug Administration. Usual therapy modalities 
included chemotherapy protocol with dacarbazine 
(DTIC) and high dose interleukin 2 (HDIL 2), but 
they did not increase the median OS, and both of 
them were limited by a low response rate (10- 
15%, and 6- 10 % respectively) (10,11). Treatment 
with IL-2 in combination with interferon-α2b (IFN-
α2b) as adjuvant immunotherapy achieves a 
response in 10–20% of patients (8). Unfortunately, 
all of these responses are generally short-lived and 
associated with high toxicity. Over time, many 
therapeutic modalities have been explored, and 
none of them is promising.  Encouragingly, in the 
recent years, the identification of the main 
genetic aberrations and signalling pathways 
involved in oncogenesis and disease progression 
has resulted in the development of novel, more 
effective therapeutic approaches (6). 
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Another question arises concerning surgical 
therapy of the olygometastatic processes in 
melanoma. A 2011 phase 2 study included 77 
patients who underwent complete resection of 
the metastatic disease and demonstrated a 
relapse free survival of five months, and around 
one third of the patients survived the following   
three years (12). 
As presented patient was on corticosteroid 
therapy, IFN-￿2b was not a treatment option. 
Rapid appearance of the local and regional 
metastases may be related to her prior immuno-
deficiency state, when corticosteroids were admini-
stered also during the surgical treatment of 
melanoma. Furthermore, because of the lack of 
deeper understanding of molecular interactions, 
we cannot discuss possible course which could 
have been taken if the corticosteroid therapy had 
been stopped and standard treatment IL-2 and IFN-
α2b had been started.  
 
Conclusion 
 
Cutaneous melanoma and its advanced-
stage forms present a systemic disease of great 
complexity which are to be further investigated 
on molecular, but also on biological and clinical 
levels. Case-related treatment brings out a lot of 
difficulties, mostly because of the incidence of 
the disease, which is growing on annual bases. 
Even though prognosis with advanced-stage 
disease is not favourable, with recent therapeutic 
advances there are chances for better survival. 
With such a therapeutic complexity, the treatment 
of patient with two or more unrelated diseases 
makes the decision even more complex. It 
requires deeper knowledge of all issues, possible 
interactions on disease-treatment relation, and 
necessarily, further investigation of therapeutic 
modalities. 
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MELANOM KOŽE KOD BOLESNIKA SA MULTIPLOM SKLEROZOM: PRIKAZ 
SLUČAJA I PREGLED LITERATURE 
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Melanom kože je maligni tumor agresivnih osobina. Regionalne ili sistemske 
metastaze predstavljaju formu širenja bolesti, ali tačno vreme pojavljivanja ne može se 
jasno definisati. Predstavljamo slučaj bolesnice sa melanomom kože, koja boluje od 
multiple skleroze i koja je na dugogodišnjoj terapiji kortikosteroidima. Primarni tumor 
bio je debljine 1,7mm (T2a), ali je klinički tok bio izuzetno agresivan sa masivnim 
potkožnim i limfatičkim metastazama, koje su uključivale  čak i zatkolene limfne 
noduse. Izvedeno je više hirurških zahvata, kao jedini terapijski izbor, u uslovima u 
kojima interferon alfa nije mogao biti primenjen zbog multiple skleroze. Bolesnica je 
umrla 16 meseci nakon dijagnoze u stadijumu generalizovane bolesti. Diskusija o 
slučaju bi trebalo da prati agesivni tok, koji može biti povezan sa imunosupresijom, ali 
to nije moglo biti jasno zaključeno. Acta Medica Medianae 2012;51(4):47-50. 
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